Pfizer Inc. (PFE) — closed signal from December 30, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 30, 2026.
Predicted vs. what happened
What happened
Reached its target in 38 days.
The thesis — published December 30, 2025
Pfizer looks like a stock that's fallen more than investors expected and could bounce back short term, helped by its dividend. Short-term momentum readings are negative and recent coverage points to weak three-year returns, so sentiment is fragile. Upcoming Phase 3 PADCEV and Keytruda data could quickly lift expectations. Only consider buying after signs the price has stabilized and keep modest upside goals.
Primary drivers
- Dividend yield may attract cautious investors if rates ease
- Positive Phase 3 PADCEV or Keytruda results could raise expectations fast
- Severely oversold condition could spark a 0-3 month bounce
- Long-term underperformance raises risk of being a value trap
How it played out
PFE: target reached in 38 days
Lyra published PFE at 24.99 on 2025-12-30 with a short-term thesis for 9% expected growth. The thesis pointed to dividend yield support, possible Phase 3 PADCEV or Keytruda data, an oversold setup that could bounce over 0-3 months, and the risk that long-term underperformance was a value trap.
Inside the window, the stock reached the 27.24 target. It peaked at 27.94 on 2026-02-11, with an 11.8% peak gain, and reached the target in 38 days. It ended the window at 27.77 on 2026-03-30. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.